Document Detail


Comparative efficacy of metformin and glibenclamide in patients with non-insulin-dependent diabetes mellitus.
MedLine Citation:
PMID:  1936477     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Metformin and glibenclamide were compared in a randomized, double-blind trial in patients with non-insulin-dependent diabetes mellitus (NIDDM) using a parallel group design. The study was performed in primary health care, and the main purpose was to assess combination therapy with the two drugs as primary treatment versus conventional oral therapy. After a 2 months diet period patients were randomized to commence treatment with either metformin, glibenclamide or the combination of both. Patients randomized to monotherapy received the alternative drug in addition if the maximal dose i.e. 3 g metformin or 14 mg glibenclamide was insufficient to normalize the fasting blood glucose concentration (FBG). Randomization and dose escalation occurred at FBG greater than or equal to 6.7 mmol/l. The titrated dose was continued for 6 months, whereafter placebo was given for 2 weeks. Seventy-two patients were randomized to either the metformin group (n = 38) or the glibenclamide group (n = 34). Fifty-six completed 6 months treatment, twenty-eight in each randomized group. Glycaemic control was unchanged after diet alone in all groups. The improvement during drug treatment was highly significant (p less than 0.001), mean FBG difference (+/- SEM) 3.2 +/- 0.4 mmol/l and mean HbA1c difference (+/- SEM) 1.5 +/- 0.2% (n = 56). There were no significant differences between patients treated solely with metformin (n = 16) and glibenclamide (n = 17) or between patients treated with a combination of glibenclamide added to metformin (n = 12) and metformin added to glibenclamide (n = 11).(ABSTRACT TRUNCATED AT 250 WORDS)
Authors:
L S Hermann; P O Bitzén; T Kjellström; F Lindgärde; B Scherstén
Related Documents :
17409127 - Corticosteroid-induced lipodystrophy is associated with features of the metabolic syndr...
16213287 - Sirolimus as primary immunosuppression agent in kidney transplant recipients: akdeniz u...
6421147 - Quality control of electrolyte analyzers. evaluation of the anion gap average.
20417447 - Comparison of the efficacy of rosuvastatin versus atorvastatin in reducing apolipoprote...
15991707 - The performance of orma boran and maasai zebu crossbreeds in a trypanosomosis endemic a...
9547777 - Phacotrabeculectomy: comparison of results from 3.5- and 5.2-mm incisions.
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Diabète & métabolisme     Volume:  17     ISSN:  0338-1684     ISO Abbreviation:  Diabete Metab     Publication Date:  1991 May 
Date Detail:
Created Date:  1991-12-26     Completed Date:  1991-12-26     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  7604157     Medline TA:  Diabete Metab     Country:  FRANCE    
Other Details:
Languages:  eng     Pagination:  201-8     Citation Subset:  IM    
Affiliation:
Department of Community Health Sciences, Dalby, Sweden.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Diabetes Mellitus, Type 2 / drug therapy*
Double-Blind Method
Drug Therapy, Combination
Female
Glyburide / therapeutic use*
Humans
Male
Metformin / therapeutic use*
Middle Aged
Chemical
Reg. No./Substance:
10238-21-8/Glyburide; 657-24-9/Metformin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The effects of oral hypoglycaemic drugs on serum lipids and lipoproteins in non-insulin-dependent di...
Next Document:  Comparative three-month study of the efficacies of metformin and gliclazide in the treatment of NIDD...